Abstract 13541: Efficacy of Cilostazol After Femoropopliteal Nitinol Stenting
Background: Restenosis after endovascular treatment of femoropopliteal (FP) artery remains a significant clinical problem. We investigated whether cilostazol would reduce restenosis in patients after stent implantation for femoropopliteal artery disease.
Methods: This study was a multicentre retrospective study. From April 2004 to December 2008, 639 limbs (511 patients, mean age 71 +/− 7 years, 71% male and mean lesion length 151+/−75mm) who underwent successful FP stenting with self-expandable nitinol stent for de novo lesions were retrospectively enrolled and divided into two groups: patients who received cilostazol (n=407 limbs) and didnot received cilostazol group (n=232 limbs) groups. All patients had a minimum follow-up of 6-month. Restenosis was defined as >2.4 of peak systolic velocity ratio by duplex or >50% stenosis by angiogram of treated lesion. Study endopoint was cumulative incidence of restenosis of treted lesion after FP stenting with nitinol stent.
Results: Mean follow-up period was 22+/−11 months. In patients who treated with cilostazol, diabetes was not more freaquent (59 vs 67%, p=0.03). Reference vessel diameter was larger compared to control group (5.2mm vs 5.0mm, p<0.001). There was no differences of other baseline characteristics between 2 group. Kaplan-Meier analysis demonstrate the binary restenosis rate at 5-year was significantly lower in cilostazol group (33.7 vs. 42.9%, p=0.0003). On multivariate analysis by Cox proportional hazard model to determine predictors of restenosis, cilostazol administration (Hazard Ratio [HR]=0.52, p<0.0001), stent fracture (HR=1.6, p=0.03), hemodialysis (HR=1.7, p=0.01) and TASCII class C/D (HR=2.4, P<0.0001) were the independent predictors of restenosis after successful FP stenting.
Conclusions: Cilostazol administration reduced restenosis after successful FP stenting with self-expandable nitinol stent.
- © 2010 by American Heart Association, Inc.